Cordycepin and a preparation from inhibit malignant transformation and proliferation by decreasing EGFR and IL-17RA signaling in a murine oral cancer model.

(CM) and its active ingredient cordycepin have been reported to inhibit tumor growth, but the mechanisms are not fully understood. This study used a mouse model for oral cancer and a cell line, 4NAOC-1 derived from the model to study the mechanisms. Our results show that a CM preparation (CMP) can significantly inhibit tumor development and malignant transformation in the model.